Supernus Pharmaceuticals Reports $165.5M Revenue in Q2 2025, Acquires Sage Therapeutics

Supernus Pharmaceuticals, Inc. reported a total revenue of $165.5 million for the second quarter of 2025, a decrease of 2% from $168.3 million in the same period of 2024. The decline was primarily attributed to a 3% drop in net product sales, which totaled $158.0 million, down from $162.5 million year-over-year. Notably, the company experienced a significant increase in sales of its ADHD treatment Qelbree, which rose by 31% to $77.5 million, while sales of APOKYN and Oxtellar XR saw declines of 26% and 61%, respectively. The company also reported net earnings of $22.5 million for the quarter, compared to $19.9 million in the prior year, resulting in earnings per share of $0.40, up from $0.36.

In terms of operational changes, Supernus completed the acquisition of Sage Therapeutics, Inc. on July 31, 2025, following a merger agreement signed on June 13, 2025. This acquisition is expected to enhance Supernus's portfolio, particularly with Sage's FDA-approved treatment for postpartum depression, ZURZUVAE. The integration of Sage is anticipated to increase net product sales and incur additional costs related to integration and amortization of intangible assets. The company also launched ONAPGO, a new subcutaneous apomorphine infusion device for Parkinson's disease, which has shown strong demand since its launch in April 2025.

Supernus's financial position improved significantly, with cash and cash equivalents rising to $144.7 million as of June 30, 2025, compared to $69.3 million at the end of 2024. Total assets increased to $1.38 billion, while total liabilities decreased to $318.5 million, reflecting a reduction in current liabilities. The company’s stockholders' equity also rose to $1.06 billion, up from $1.04 billion at the end of the previous fiscal year. The increase in cash was primarily due to improved cash flows from operating activities, which provided $89.1 million in the first half of 2025, compared to $74.0 million in the same period of 2024.

The company reported a decrease in research and development expenses, which totaled $22.1 million for the second quarter, down from $26.2 million in the prior year. This reduction was mainly due to lower clinical program costs associated with SPN-820, partially offset by increased costs for SPN-817. Selling, general, and administrative expenses also rose to $93.6 million, reflecting higher professional and consulting fees. The effective tax rate for the quarter was significantly lower at 35%, compared to 24.3% in the previous year, primarily due to a state tax refund.

Looking ahead, Supernus anticipates that the acquisition of Sage will lead to increased sales and operational costs, while also expecting variability in profitability due to market pressures and the loss of patent exclusivity for certain products. The company remains focused on its pipeline of CNS treatments and plans to continue investing in research and development to support future growth.